Idexx Laboratories has steadily increased its scale and reach in the veterinary diagnostic lab business to dig a narrow moat. It is well-positioned to benefit from two key trends. First, pet ownership ...
For the quarter ended September 2024, Idexx Laboratories (IDXX) reported revenue of $975.54 million, up 6.6% over the same period last year. EPS came in at $2.80, compared to $2.53 in the year-ago ...
Idexx Laboratories (IDXX) reported $1.11 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 10.6%. EPS of $3.63 for the same period compares to $2.44 a year ...
Zacks Investment Research on MSN
Why is Idexx (IDXX) up 0.5% since last earnings report?
It has been about a month since the last earnings report for Idexx Laboratories (IDXX). Shares have added about 0.5% in that time frame, outperforming the S&P 500. But investors have to be wondering, ...
The launch of the Catalyst ® Pancreatic Lipase Test demonstrates IDEXX's (IDXX) Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than ...
Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive ...
Idexx posted second-quarter results that were more muted than usual; we’re leaving our fair value estimate unchanged as our slight adjustments to full-year projections weren’t enough to move the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results